Drug profile

The FDA adverse-event record for Gentamicin Sulfate, Usp; Mometasone Furoate Anhydrous, Usp; Clotrimazole, Usp

64 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Gentamicin Sulfate, Usp; Mometasone Furoate Anhydrous, Usp; Clotrimazole, Usp. See the species affected, top reactions, and outcomes below.

64
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
31
Loss of hearing - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
64
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Gentamicin Sulfate, Usp; Mometasone Furoate Anhydrous, Usp; Clotrimazole, Usp

Administration Routes

Auricular (Otic)TopicalOral

Species Affected

Dog 63
Cat 1

Most Affected Breeds

Retriever - Labrador 8
Terrier (unspecified) 6
Terrier - Yorkshire 5
Shepherd Dog - German 4
Dog (unknown) 3
American Pit Bull Terrier 3
Papillon - Spaniel - Continental Toy (with erect ears or with dropped ears (Phaléne)) 2
Pinscher - Miniature 2
Boxer (German Boxer) 2
Maltese 2

Most Reported Reactions

Loss of hearing 31
Deafness 24
Drug administration duration too long 3
Application site pain 3
Ear discharge 3
Not himself/herself 3
Drug dose administration interval too short 2
Medication error NOS 2
Vomiting 2
Nervous 2
Behavioural disorder NOS 2
Lethargy (see also Central nervous system depression in Neurological) 2

Outcome Breakdown

Outcome Unknown
28 (43.8%)
Recovered with Sequela
25 (39.1%)
Recovered/Normal
9 (14.1%)
Ongoing
2 (3.1%)

Gentamicin Sulfate, Usp; Mometasone Furoate Anhydrous, Usp; Clotrimazole, Usp Adverse Event Insights

64 reports name Gentamicin Sulfate, Usp; Mometasone Furoate Anhydrous, Usp; Clotrimazole, Usp; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Gentamicin Sulfate, Usp; Mometasone Furoate Anhydrous, Usp; Clotrimazole, Usp. Administration routes: Auricular (Otic), Topical, Oral.

By species: Dog (63 reports), Cat (1 reports). By breed: Retriever - Labrador (8), Terrier (unspecified) (6), Terrier - Yorkshire (5).

Leading clinical signs: Loss of hearing (31), Deafness (24), Drug administration duration too long (3), Application site pain (3). Outcome, 64 coded reports: Outcome Unknown leads at 43.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.